肠直肠敏感性与胃肠介导的葡萄糖排放相关,但不与蛋白效应相关
Sondre Meling1,2, Erling Tjora2,3, Heike Eichele4,5
1Department of Medicine, Stavanger University Hospital, Stavanger, Norway.
Endocrinology, diabetes & metabolism
|December 7, 2023
概括
在2型糖尿病中存在直肠过敏,并与胃肠道的葡萄糖处理有关,而不是因克雷丁的作用. 英克雷丁的作用和胃肠介导的葡萄糖排放都与糖尿病的严重程度和持续时间相关.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 神经学 神经学
背景情况:
- 在2型糖尿病 (T2D) 中因克雷丁效应的减弱还没有完全被理解,而管传输受损是潜在的因素.
- 自主神经病变可能导致T2D中因克列反应和葡萄糖调节的改变.
研究的目的:
- 调查T2D患者内因克列效应与自主神经病变之间的关联.
- 探索自主神经病变,隐素效应,失糖症程度和糖尿病持续时间之间的关系.
主要方法:
- 一项横截面研究包括患有长期T2D,近期T2D和对照的参与者.
- 使用心血管反射测试,心率变化,运动功能和直肠气球膨胀来评估自主神经功能.
- 使用口服葡萄糖耐受性测试和静脉注射葡萄糖输液计算了隐素效应和胃肠介导葡萄糖排放 (GIGD).
主要成果:
- 与对照组相比,患有T2D的参与者表现出直肠过敏症 (p=0.005).
- 肠直肠过敏与隐素效应没有关联 (p=0.106),但与GIGD有关 (p=0.005).
- 无论是英克雷丁效应还是GIGD,都与葡萄糖水平,HbA1c和糖尿病持续时间相关.
结论:
- 在早期和长期的T2D中存在直肠过敏,这表明内脏神经病变.
- 视觉神经病变与胃肠道葡萄糖处理 (GIGD) 的受损有关,而不是直接与素效应有关.
- 隐形素效应和GIGD受T2D的严重程度和持续时间的影响.
更多相关视频
07:29Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation
Published on: December 29, 2023
668
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
11.0K
相关概念视频
Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
Glucose Absorption Into the Small Intestine
31.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.7K
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
